Technical analysis of Artiva Biotherapeutics, Inc. (ARTV): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology firm specializing in the development of natural killer (NK) cell-based treatments for individuals afflicted with autoimmune disorders and various forms of cancer. Its flagship therapeutic candidate, AB-101, is an innovative, ready-to-use (off-the-shelf) NK cell therapy.
Price Performance
| 1 month | -26.37% |
| 3 months | -12.42% |
| Year-to-date | +100.47% |
| 1 year | +277.19% |
52-Week Range
| 52-week High | $14.53 |
| 52-week Low | $2.22 |
| Avg Volume (90d) | 522K |
Technical Indicators
| SMA 50 | $10.62 |
| SMA 200 | $7.64 |
| Beta | 1.48 |
| 30-day Volatility (annualised) | 56.2% |
| Price vs SMA 50 | -19.0% |
| Price vs SMA 200 | +12.6% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $4.17 | |
| 2025-11 | $3.76 | -9.8% |
| 2025-12 | $4.29 | +14.1% |
| 2026-01 | $3.89 | -9.3% |
| 2026-02 | $5.82 | +49.6% |
| 2026-03 | $6.44 | +10.7% |
| 2026-04 | $10.24 | +59.0% |
| 2026-05 | $7.93 | -22.6% |
| 2026-06 | $9.70 | +22.3% |
| 2026-07 | $10.10 | +4.1% |
| 2026-08 | $11.30 | +11.9% |
| 2026-09 | $8.60 | -23.9% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | |
| 2026-09-14 | | $144M |
| 2026-09-14 | | $898M |
Price
| Price | $8.60 |
| Market Cap | $420M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.98 |
| EV / EBITDA | -2.38 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.03 |
| Current Ratio | 24.16 |